Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) SVP Jonathan Rubin Sells 927 Shares

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) SVP Jonathan Rubin sold 927 shares of the business’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the transaction, the senior vice president now owns 7,853 shares in the company, valued at approximately $307,444.95. The trade was a 10.56 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Supernus Pharmaceuticals Trading Up 0.4 %

Shares of SUPN opened at $32.81 on Wednesday. The company has a market cap of $1.81 billion, a price-to-earnings ratio of 30.66 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $40.28. The company’s fifty day simple moving average is $37.34 and its 200 day simple moving average is $35.39.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SUPN. Pacer Advisors Inc. boosted its position in Supernus Pharmaceuticals by 29.9% during the third quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock worth $54,655,000 after purchasing an additional 403,028 shares during the period. Woodline Partners LP boosted its position in Supernus Pharmaceuticals by 124.8% during the fourth quarter. Woodline Partners LP now owns 423,828 shares of the specialty pharmaceutical company’s stock worth $15,326,000 after purchasing an additional 235,257 shares during the period. BNP Paribas Financial Markets boosted its position in Supernus Pharmaceuticals by 248.0% during the fourth quarter. BNP Paribas Financial Markets now owns 292,629 shares of the specialty pharmaceutical company’s stock worth $10,581,000 after purchasing an additional 208,552 shares during the period. Raymond James Financial Inc. bought a new position in Supernus Pharmaceuticals during the fourth quarter worth $6,847,000. Finally, Great Lakes Advisors LLC bought a new position in Supernus Pharmaceuticals during the fourth quarter worth $6,131,000.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald downgraded shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $57.00 to $36.00 in a report on Wednesday, February 19th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.